BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22869417)

  • 1. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
    Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
    Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
    Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
    Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of treatment response to ¹³¹I therapy by diffuse hepatic uptake intensity on post-therapy whole-body scan in patients with distant metastases of differentiated thyroid cancer.
    Jun S; Lee JJ; Park SH; Kim TY; Kim WB; Shong YK; Ryu JS
    Ann Nucl Med; 2015 Aug; 29(7):603-12. PubMed ID: 25980591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer.
    Toubeau M; Touzery C; Arveux P; Chaplain G; Vaillant G; Berriolo A; Riedinger JM; Boichot C; Cochet A; Brunotte F
    J Nucl Med; 2004 Jun; 45(6):988-94. PubMed ID: 15181134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
    Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
    Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer.
    Kendler DB; Vaisman F; Corbo R; Martins R; Vaisman M
    Clin Nucl Med; 2012 Jun; 37(6):545-9. PubMed ID: 22614184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of different clinical and pathological variables in patients with differentiated thyroid cancer on successful ablation for 3700 MBq (131)I: a single Egyptian institutional experience over 14 years.
    Husseini MA
    Ann Nucl Med; 2016 Aug; 30(7):468-76. PubMed ID: 27194041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
    Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
    J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131).
    Prpic M; Dabelic N; Stanicic J; Jukic T; Milosevic M; Kusic Z
    Ann Nucl Med; 2012 Nov; 26(9):744-51. PubMed ID: 22829399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
    Cherk MH; Francis P; Topliss DJ; Bailey M; Kalff V
    Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
    Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
    J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
    Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
    Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.